Rosenblatt raised the firm's price target on Nexxen to $16 from $15 and keeps a Buy rating on the shares. Nexxen's Q4 results showed declines in ex-TAC contribution and EBITDA in line with guidance, driven by supply path resets from a major DSP partner, though ramping spend with this partner in early 2026 is expected to alleviate the issue, the analyst tells investors in a research note.
